Skip to main content

Table 2 Univariate analysis of OS in the primary cohorts

From: Establishment and validation of a predictive nomogram model for non-small cell lung cancer patients with chronic hepatitis B viral infection

Variable Univariate analysis
HR (95% CI) P
Gender
 Male Reference  
 Female 1.088 (0.678–1.746) 0.726
Age (years)
 ≤ 42 Reference  
 > 42 0.316 (0.171–0.587) < 0.001
Family history   
 Yes Reference  
 No 0.877 (0.512–1.501) 0.631
Smoking behaviour
 Yes Reference  
 No 0.965 (0.595–1.564) 0.884
BMI
 ≥ 25 Reference  
 18.5 ≤ BMI < 25 1.419 (0.757–2.660) 0.275
 < 18.5 1.489 (0.480–4.618) 0.491
TNM stage
 I Reference  
 II 1.058 (0.318–3.517) 0.927
 III 3.256 (1.477–7.181) 0.003
 IV 6.575 (2.939–14.711) < 0.001
Size (cm)d
 ≤ 6.3 Reference  
 > 6.3 2.769 (1.503–5.101) 0.001
Treatment
 Surgery Reference  
 Radiotherapy/chemotherapy 3.737 (1.891–7.387) < 0.001
 Surgery and radiotherapy/chemotherapy 1.049 (0.517–2.126) 0.895
 Other 6.845 (2.630–17.818) < 0.001
ALT (U/L)
 ≤ 12.5 Reference  
 > 12.5 0.630 (0.311–1.278) 0.200
AST (U/L)
 ≤ 22.0 Reference  
 > 22.0 1.366 (0.849–2.197) 0.198
SLR
 ≤ 1.24 Reference  
 > 1.24 1.673 (1.015–2.759) 0.044
APOAI (g/L)
 ≤ 1.17 Reference  
 > 1.17 0.393 (0.244–0.633) < 0.001
APOB (g/L)
 ≤ 0.99 Reference  
 > 0.99 0.533 (0.308–0.922) 0.024
ALP (U/L)
 ≤ 82.9 Reference  
 > 82.9 1.800 (1.106–2.929) 0.018
ALB (g/L)
 ≤ 40.1 Reference  
 > 40.1 0.693 (0.385–1.246) 0.220
GGT (U/L)
 ≤ 44.2 Reference  
 > 44.2 2.371 (1.348–4.169) 0.003
LDH (U/L)
 ≤ 245.6 Reference  
 > 245.6 3.423 (1.847–6.345) < 0.001
TBIL (μmol/L)
 ≤ 13.6 Reference  
 > 13.6 0.541 (0.276–1.059) 0.073
DBIL (μmol/L)
 ≤ 3.3 Reference  
 > 3.3 1.583 (0.974–2.572) 0.064
  1. BMI body mass index, TNM pathological tumour node metastasis stage, ALT alanine transaminase, AST aspartate aminotransferase, SLR AST-to-ALT ratio, APOAI apolipoprotein AI, APOB apolipoprotein B, ALP alkaline phosphatase, ALB albumin, GGT glutamyl transpeptidase, LDH lactic dehydrogenase, TBIL total bilirubin, DBIL direct bilirubin